Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014168727 - FIXED DOSE COMBINATION TREATMENT FOR SCHIZOPHRENIA

Publication Number WO/2014/168727
Publication Date 16.10.2014
International Application No. PCT/US2014/028283
International Filing Date 14.03.2014
IPC
A61P 25/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
CPC
A61K 31/137
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine ; or methadone
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/551
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogen atoms, e.g. dilazep
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants
  • SHIRE LLC [US]/[US] (AllExceptUS)
Inventors
  • HUTSON, Peter, Haynes
  • DIRKS, Bryan, Larry
  • SHOJAEI, Amir
Agents
  • ZAGAR, Paul, M.
Priority Data
61/793,98315.03.2013US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) FIXED DOSE COMBINATION TREATMENT FOR SCHIZOPHRENIA
(FR) POLYTHÉRAPIE À DOSE FIXÉE POUR LA SCHIZOPHRÉNIE
Abstract
(EN)
The present invention relates to a fixed dosage unit, and methods for treating schizophrenia comprising administering the fixed dosage unit. More specifically, the present invention relates to a fixed dosage unit that reduces the incidence or degree of adverse effects that are associated with atypical antipsychotic drug therapy. The present invention relates to the field of pharmaceutical dosage forms and methods for treatment. More particularly, the present invention relates to a fixed dosage unit including lisdexamfetamine dimesylate and an atypical antipsychotic drug, and methods for treating schizophrenia comprising administering the fixed dosage unit.
(FR)
La présente invention concerne une unité posologique fixe, ainsi que des méthodes pour le traitement de la schizophrénie consistant à administrer l'unité posologique fixe. Plus spécifiquement, la présente invention concerne une unité posologique fixe qui réduit l'incidence ou le degré des effets indésirables qui sont associés à une pharmacothérapie antipsychotique atypique. La présente invention se rapporte au domaine des formes posologiques pharmaceutiques et aux méthodes de traitement. Plus particulièrement, cette invention concerne une unité posologique fixe incluant du dimésylate de lisdexamfétamine et un médicament antipsychotique atypique, ainsi que des méthodes de traitement de la schizophrénie consistant à administrer l'unité posologique fixe.
Latest bibliographic data on file with the International Bureau